Clinical Trial Update: Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer [Phase 2]

View source ↗

Summary

A Pfizer-sponsored Phase 2 trial evaluating bosutinib (SKI-606) in breast cancer, including metastatic disease, has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bosutinib (bosutinib)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2013-01-31